StreetAlpha.app
Home › Stocks › PCVX

Vaxcyte, Inc. (PCVX)

Healthcare
$55.39
▼ −5.09%
LAST CLOSE · NOV 20

Vaxcyte is developing pneumococcal vaccines for adults and children, made with its XpressCF protein production platform. It last closed at $55.39 on Nov 20, down 5.09% on the day. The next earnings report for PCVX is expected around Tue, Feb 23, 2027, after the close. For the quarter ended Sep 2026, PCVX reported EPS of -$1.99. Over its last 8 reports the stock moved an average of 5.6% the session after earnings. Over the last 12 months PCVX insiders bought $0 of stock on the open market and sold $13.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is PCVX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PCVX.

Key Stats

Last 12 months
Results
Net income
−$1.1B
EPS (diluted)
−$8.05
Free cash flow
−$974.4M
Valuation
Market cap
$8.8B
158.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$125.5M
At Sep 30
Shareholder equity
$2.5B
Shares outstanding
158.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$100.1M−$100.1MFY2021FY2022: −$223.5M−$223.5MFY2022FY2023: −$402.3M−$402.3MFY2023FY2024: −$463.9M−$463.9MFY2024FY2025: −$766.6M−$766.6MFY2025

From PCVX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 23
Estimated date · After the close
Reported EPS
-$1.99
Quarter ended Sep 2026
Year ago EPS
-$1.56
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.02Dec '24Mar 2025: -$1.04Mar '25Jun 2025: -$1.22Jun '25Sep 2025: -$1.56Sep '25Dec 2025: -$1.80Dec '25Mar 2026: -$2.30Mar '26Jun 2026: -$1.97Jun '26Sep 2026: -$1.99Sep '26Latest -$1.99
Revenue by quarter
Not enough quarters on file yet.
How PCVX moved after its last 8 reports
Average move the session after a report ±5.6%
Nov 4, 2026After the close−5.7%
Aug 5, 2026After the close+5.3%
May 6, 2026After the close−9.8%
Feb 24, 2026After the close+2.8%
Nov 4, 2025After the close−2.5%
Aug 6, 2025After the close−9.1%
May 7, 2025After the close+8.4%
Feb 25, 2025After the close−0.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PCVXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PCVX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PCVX

Technical Analysis

PCVX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 12% below its 20 day and 12% below its 50 day average. It is 4% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the swing low (Sep 24) at $55.09, and the nearest resistance the Pivot at $56.38.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 5.9%/day
Key levels
$90.7552 week high+63.8%
$62.1820 day average+12.3%
$62.1150 day average+12.1%
$60.25100 day average+8.8%
$57.79200 day average+4.3%
$57.49Pivot R1+3.8%
$57.03Swing high (Jul 28)+3.0%
$56.38Pivot+1.8%
$55.39Last close
$55.09Swing low (Sep 24)−0.5%
$54.28Pivot S1−2.0%
$42.4052 week low−23.5%
Indicators
RSI (14)36.90Weak, oversold below 30Neutral
MACD-1.10Below its signal lineBearish
Stochastic5.2Near the bottom of its rangeOversold
ADX (14)20.9Weak trend
Williams %R-99.1Oversold below −80, overbought above −20Oversold
CCI (20)-179.7Oversold below −100, overbought above 100Oversold
Rate of change−13.3%Change over 10 sessionsBearish
ATR (14)$3.25Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PCVX

What happened before

See how PCVX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PCVX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PCVX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PCVXHow many large options trades hit PCVX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

PCVX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲197 buying vs 142 selling
  • ▲Held by funds +2.0 pts
  • ▲Funds holding +22
  • ▼Superinvestors: 1 added, 3 cut
  • ▲Put/call 2.09 to 1.63
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding357335+6.6%
In funds' top 101014−28.6%
Held by funds107.9%105.9%+2.0 pts
New / increased65 / 13247 / 132+10.1%
Reduced / sold out100 / 42100 / 51−6.0%
Put/call ratio1.632.09−22.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PCVX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PCVX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$13.9M26 sales · 5 insiders
90% of the selling was under pre-arranged trading plans.
2025-12 sold $1.0M2026-03 sold $687K2026-04 sold $311K2026-05 sold $128K2026-06 sold $3.3M2026-07 sold $1.7M2026-08 sold $1.6M2026-09 sold $376K2026-10 sold $3.3M2026-11 sold $1.5MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 11Harpreet S. DhaliwalChief Technical Ops OfficerSale plan17,000$67.83$1.2M
Nov 2Jim WassilEVP, Chief Scientific Ofc, COOSale plan2,250$60.90$137K
Nov 2Elvia CowanSVP, Finance & CAOSale plan3,000$60.92$183K
Oct 5Jim WassilEVP, Chief Scientific Ofc, COOSale plan18,000$86.74$1.6M
Oct 5Elvia CowanSVP, Finance & CAOSale plan19,000$86.74$1.6M
Oct 1Jim WassilEVP, Chief Scientific Ofc, COOSale plan2,250$56.67$128K
Every insider buy and sale for PCVX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PCVX insider trades →

From SEC Form 4 filings by PCVX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PCVX is in one of them and how their past PCVX trades turned out.

PCVX in the AI portfolios
Loading…

PCVX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PCVX in an article yet. Here's the latest on the wider market.

PCVX in the news

PCVX Congress Trades

All congress trades →
Trades, 12 months
3
Buys
3
100%
Sells
0
0%
People
1
Last filed Sep 4
Who traded PCVX · since 2022
Latest 5 filings of 8
$1K – $15KTraded Jul 16, 2026Filed Sep 4, 2026
$1K – $15KTraded May 13, 2026Filed Jun 8, 2026
$1K – $15KTraded May 12, 2026Filed Jun 8, 2026
$1K – $15KTraded Apr 28, 2025Filed May 6, 2025
$1K – $15KTraded Apr 15, 2025Filed May 6, 2025
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KJul 16, 2026Sep 4, 202650 d
Gilbert CisnerosD · CABuy$1K – $15KMay 13, 2026Jun 8, 202626 d
Gilbert CisnerosD · CABuy$1K – $15KMay 12, 2026Jun 8, 202627 d
Gilbert CisnerosD · CABuy$1K – $15KApr 28, 2025May 6, 20258 d
Gilbert CisnerosD · CABuy$1K – $15KApr 15, 2025May 6, 202521 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Vaxcyte

Vaxcyte is a biotechnology company based in San Carlos, California, that is developing vaccines to protect against bacterial diseases. Its main focus is pneumococcal vaccines, which guard against infections caused by Streptococcus pneumoniae bacteria, including pneumonia and meningitis. The company uses XpressCF, a protein production platform that does not rely on living cells, to make these complex vaccines. Its candidates are still in clinical trials for adults and infants, so they are not yet sold.

Headquarters
San Carlos, CA